Search company, investor...

Bionovo

bionovo.com

Founded Year

2002

Stage

Unattributed VC | Alive

Total Raised

$15.78M

Last Raised

$15.78M | 16 yrs ago

About Bionovo

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

Headquarters Location

5858 Horton Street Suite 400

Emeryville, California, 94608,

United States

510-601-2000

Missing: Bionovo's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bionovo's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bionovo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bionovo is included in 3 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,482 items

Startups focused on providing products and services catering to women's health and wellbeing.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Bionovo Patents

Bionovo has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/28/2011

9/20/2016

Menstrual cycle, Human female endocrine system, Diabetes, Menstrual disorders, Gynaecology

Grant

Application Date

11/28/2011

Grant Date

9/20/2016

Title

Related Topics

Menstrual cycle, Human female endocrine system, Diabetes, Menstrual disorders, Gynaecology

Status

Grant

Latest Bionovo News

Bionovo Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 4, 2016

Bionovo, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 18:36 EST 4 Dec 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Bionovo, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Bionovo, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bionovo, Inc. since January 2007. Key Findings Provides intelligence on Bionovo, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Bionovo, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Bionovo, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Bionovo, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Bionovo Frequently Asked Questions (FAQ)

  • When was Bionovo founded?

    Bionovo was founded in 2002.

  • Where is Bionovo's headquarters?

    Bionovo's headquarters is located at 5858 Horton Street, Emeryville.

  • What is Bionovo's latest funding round?

    Bionovo's latest funding round is Unattributed VC.

  • How much did Bionovo raise?

    Bionovo raised a total of $15.78M.

  • Who are the investors of Bionovo?

    Investors of Bionovo include Mallette Capital Management, Ironwood Capital, Hillview Capital Advisors, Atlas Capital Management, Paramount BioCapital Asset Management and 6 more.

  • Who are Bionovo's competitors?

    Competitors of Bionovo include Oligomerix, Cerecin, Alucent Biomedical, Array Biopharma, Innate Pharma and 14 more.

Compare Bionovo to Competitors

T
Trellis Bioscience

Trellis Bioscience provides health care products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments.

Cerecin Logo
Cerecin

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

K
Kemia

Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.

A
Angel Biotechnology

Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.

N
Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.